초록 ▼

Described is a method for the preparation of a mixture of peptides having a cysteine content between 7-20 w/w % from a protein source, comprising cysteine containing proteins, comprising the steps of: a) cleaving the proteins of the protein source into peptides; b) digesting the peptides obtained

Described is a method for the preparation of a mixture of peptides having a cysteine content between 7-20 w/w % from a protein source, comprising cysteine containing proteins, comprising the steps of: a) cleaving the proteins of the protein source into peptides; b) digesting the peptides obtained in step a) by an exopeptidase, the action of which is at least attenuated at the position of a cysteine in the peptide, therewith forming digested peptides having a terminal cysteine; c) purifying the digested peptides, and the use of the preparation as active component in a medicament, especially for the treatment of conditions mediated by oxidative damage and for the elevation of cellular glutathion levels in the human or animal body.

대표청구항 ▼

Described is a method for the preparation of a mixture of peptides having a cysteine content between 7-20 w/w % from a protein source, comprising cysteine containing proteins, comprising the steps of: a) cleaving the proteins of the protein source into peptides; b) digesting the peptides obtained

Described is a method for the preparation of a mixture of peptides having a cysteine content between 7-20 w/w % from a protein source, comprising cysteine containing proteins, comprising the steps of: a) cleaving the proteins of the protein source into peptides; b) digesting the peptides obtained in step a) by an exopeptidase, the action of which is at least attenuated at the position of a cysteine in the peptide, therewith forming digested peptides having a terminal cysteine; c) purifying the digested peptides, and the use of the preparation as active component in a medicament, especially for the treatment of conditions mediated by oxidative damage and for the elevation of cellular glutathion levels in the human or animal body. apy for long-term expression in erythropoietin in rats. Proc. Natl. Acad. Sci. USA 92: 8055-8058, Aug. 1995.* Raz et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl. Acad. Sci. USA 90: 4523-4527, May 1993.* Tripathy et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vector. Nature Medicine 2(5): 545-550, May 1996.* Dhawan et al. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 254: 1509-1512, Dec. 1991.* Orkin and Motulsky. Report and recommendations of the panel to assess the NIH investment in research on gene therapy, Dec. 1995.* Friedmann, T. Overcoming the obstacles to gene therapy. Sci. Am. Jun. 1997. pp. 96-101, Jun. 1997.* Tripathy et al. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc. Natl. Acad. Sci. USA 91: 11557-11561, Nov. 1994.* Verma et al. Gene therapy--promises, problems and prospects. Nature 389: 239-242, Sep. 1997.* Tripathy, et al., "Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors", Nature Med. 2:545-550 (1996). Tripathy et al., "Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus", Proc. Natl. Acad. Sci. USA 91:11557-11561 (1994). Barr et al., "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus", Gene Ther. 1:51-58 (1994). Barr et al., "Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains", Gene Ther. 2:151-155 (1995). Kass et al., "The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer", Gene Ther. 1:395-402 (1994). Mastrangeli et al., "Sero-Switch" Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype, Hum. Gene Ther. 7:79-87 (1996). Yang et al., "Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo", Gene Ther. 3:137-144 (1996). Brody et al., "Acute Responses of Non-Human Primates to Airway Delivery of an Adenovirus Vector Containing the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA", Human Gene Ther. 5:821-836 (1994). Yang et al., "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy", Proc. Natl. Acad. Sci USA 91:4407-4411 (1994). Yang et al., Clearance of Adenovirus-Infected Hepatocytes by MHC Class 1-Restricted CD4+CTLs in Vivo, J. Immunol. 155:2564-2570 (1995). Dhawan et al., "Systemic Delivery of Human Growth Hormone by Injection of Genetically Engineered Myoblasts", Science 254:1509-1512 (1991). Barr and Leiden, "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts", Science 254: 1507-1509 (1991). Yao, S. and Kurachi, K., "Expression of human factor IX in mice after injection of genetically modified myoblasts", PNAS USA 9:3357-3361 (1992). Partridge et al., "Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts", Nature 337:176-179 (1989). Dai et al., "Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo", PNAS USA 89: 10892-5 (1992). Hamamori et al., "Persistent Erythropoiesis by Myoblast transfer of Erythropoietin cDNA", Hum. Gene Ther. 5:1349-1356 (1994). Hamamori et al., "Myoblast Transfer of Human Erythropoietin Gene in a Mouse Model of Renal Failur e", J. Clin. Invest. 95:1808-1813 (1995). Kay et al., "In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs", PNAS USA 91:2353-7 (1994). Rosenfeld, et al., "Adenovirus-Mediated Transfer of a Recombinant α1-Antitrypsin Gene to the Lung Epithelium in Vivo", Science 252:431-434 (1991). Lemarchand et al., "Adenovirus-mediated transfer of a recombinant human α1-antitrypsin cDNA to human endothelial cells", PNAS USA 89:6482-6 (1992). Vincent et al., "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene", Nat. Genet. 5:130-4 (1993). Engelhardt et al., "Prolonged Transgene Expression in Cotton Rat Lung with Recombinant Adenoviruses Defective in E2a", Hum. Gene Ther. 5:1217-29 (1994). Mendell et al., "Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy", N. Engl. J. Med. 333:832-8 (1995). Morgan, J.E., "Cell and Gene Therapy in Duchenne Muscular Dystrophy", Hum. Gene Ther. 5:165-73 (1994). Dai et al., "Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression", PNAS USA 92:1401-5 (1995). Yang et al., "Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses", J. Virol. 69:2004-15 (1995). Yang et al., "MHC Class 1-Restricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with E1-Deleted Recombinant Adenoviruses", Immunity 1:433-42 (1994). Wolff et al., "Direct Gene Transfer into Mouse Muscle in Vivo", Science 247:1465-1468 (1990). Wolff et al., "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle", Hum. Mol. Gen. 1:363-9 (1992). Manthorpe et al., "Gene Therapy by Intramuscular Injection of Plasmid DNA: Studies on Firefly Luciferase Gene Expression in Mice", Hum. Gene Ther. 4:419-31 (1993). Setoguchi, et al., Stimulation of Erythropoiesis by In Vivo Gene Therapy: Physiologic Consequences of Transfer of the Human Erythropoietin Gene to Experimental Animals Using an Adenovirus Vector, Blood 84:2946 (1994).